Results 101 to 110 of about 189,589 (267)

Portal vein thrombosis with contrast‐enhanced ultrasound in a patient with hepatocellular carcinoma: a case study [PDF]

, 2012
Saba Salman
openalex   +1 more source

Open Questions in Surgery for Hepatoblastoma: A Joined SIOPEL‐IPSO Survey

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Surgery is pivotal in the management of hepatoblastoma (HB) although approaches and techniques may vary. The Liver Group of the International Society of Pediatric Oncology (SIOPEL) and the International Pediatric Surgical Oncology (IPSO) group collaborated to develop an online survey to investigate specific technical aspects and ...
Chiara Grimaldi, Francesca Gigola, Reto M. Baertschiger, Marco Del Riccio, Hanna Garnier, Gloria Gonzalez, York Tien Lee, Amos Loh, Luca Pio, Sophie Branchereau   +9 more
wiley   +1 more source

Giant Splenorenal Shunt in a Young Patient with Autoimmune Hepatitis/Primary Biliary Cholangitis Overlap Syndrome and Portal Vein Thrombosis [PDF]

, 2017
Fabrizio Chegai, Armando Ugo Cavallo, Marco Forcina, V. Giuricin, Francesca Castellani, Laura Greco, Matteo Manuelli, Tommaso Maria Manzia, Gianluigi Sergiacomi   +8 more
openalex   +1 more source

Superior Mesenteric Vein Aneurysm With Arteriovenous Communication and Portal Vein Thrombosis: A Rare Presentation in Non-cirrhotic Portal Hypertension [PDF]

, 2023
Pagadala Naga Balaji Nitesh, Biju Pottakkat, Raja Kalayarasan   +2 more
openalex   +1 more source

Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM‐POWR Study

European Journal of Haematology, EarlyView.
ABSTRACT Objectives To assess the effectiveness and safety of damoctocog alfa pegol in patients with severe and nonsevere hemophilia A in the fifth interim analysis of the ongoing HEM‐POWR study. Methods HEM‐POWR (NCT03932201) is a multinational, Phase 4, prospective observational study.
Mark T. Reding, María Teresa Alvarez Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Kathrin Schmidt, Johannes Oldenburg   +7 more
wiley   +1 more source

Improvement of image quality and assessment of respiratory motion for hepatocellular carcinoma with portal vein tumor thrombosis using contrast-enhanced four-dimensional dual-energy computed tomography

, 2021
Shingo Ohira, Naoyuki Kanayama, Kentaro Wada, Toshiki Ikawa, Takero Hirata, Noriko Kishi, Tsukasa Karino, Hayate Washio, Yoshihiro Ueda, Masayoshi Miyazaki, Masahiko Koizumi, Teruki Teshima   +11 more
openalex   +2 more sources

Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis

Hepatology Research, EarlyView.
ABSTRACT Background Hepatocellular carcinoma (HCC) with Vp4 portal vein tumor thrombosis (PVTT) has an extremely poor prognosis, and evidence for effective systemic therapy is limited. Preclinical studies suggest that hypofractionated radiation therapy (HFRT) may enhance immune checkpoint inhibitor (ICI) efficacy through immunogenic cell death and ...
Masahiko Tameda, Hideaki Tanaka, Yutaka Toyomasu, Mizuki Kawachi, Hirono Owa, Mone Tsukimoto, Yasuyuki Tamai, Naoto Fujiwara, Ryuta Shigefuku, Suguru Ogura, Yoshihito Nomoto, Hayato Nakagawa   +11 more
wiley   +1 more source

Value of Protein C and D-Dimer in Predicting Non Hepatocellular Carcinoma Portal Vein Thrombosis in Patients with Liver Cirrhosis [PDF]

, 2016
Sahar El-Nemr, Sherief Galal, Hoda El-Hady, Naglaa Khalifa   +3 more
openalex   +1 more source

A very rare case of splenosis and acquired chronic non‐cirrhotic portal vein thrombosis with cavernous transformation

, 2022
Aliya Kadyrova, Iliar Baudinov, Elmira Mamytova, Kubat Ibraimov, Tynarbek Arzykulov, Сагынали Маматов, Yethindra Vityala, Tugolbai Tagaev   +7 more
openalex   +1 more source

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source